The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: Results of a phase IIB randomized, double‐blind, placebo‐controlled, dose‐ranging trial
Arthritis & Rheumatism2006Vol. 54(5), pp. 1390–1400
Citations Over TimeTop 1% of 2006 papers
Paul Emery, Roy Fleischmann, Anna Filipowicz‐Sosnowska, Joy Schechtman, L Szczepański, Arthur Kavanaugh, Artur Racewicz, Ronald van Vollenhoven, Nicole F. Li, Sunil Agarwal, E. Hessey, T Shaw
Abstract
Both rituximab doses were effective and well tolerated when added to MTX therapy in patients with active RA. The primary end point (ACR20 response) was independent of glucocorticoids, although intravenous glucocorticoid premedication improved tolerability during the first rituximab infusion.
Related Papers
- → Controlled trial of methylprednisolone pulses and low dose oral prednisone for the minimal change nephrotic syndrome.(1985)80 cited
- → Association between handgun purchase and mortality from firearm injury(2003)72 cited
- → Pulsed methylprednisolone therapy compared to high dose prednisone in systemic lupus erythematosus nephritis(1986)17 cited
- The different lente glucocorticoid effect of remission induction on children with nephrotic syndrome(2011)
- [Controlled trials of premedication of fiberendoscopy (author's transl)].(1978)